Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak
NCT ID: NCT04416360
Last Updated: 2023-05-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
35 participants
INTERVENTIONAL
2020-05-05
2020-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19
NCT04460677
Impact of Combined Medication and Behavioral Treatment for ASD & ADHD
NCT03242772
Digital-based Psychosocial Intervention for Parents of Children With Neurodevelopmental Disorders
NCT06303791
Assessment of the Benefit of Teleconsultations for Children With Autism Spectrum Disorders
NCT02996708
Parents as Friendship Coaches for Children With ADHD
NCT04086979
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There is little evidence about the impact of prolonged confinement in these children. The first clinical observations, at the beginning of confinement, reported various situations. Some children showed marked emotional disturbances, whereas others seem to be happy with less social pressure. For ASDs, the ritualization can be a stabilizing factor. For ADHDs, the decrease in school pressure is undoubtedly a positive factor. The availability of parents to create a suitable environment could play a major role. In all cases, changes in care management (teleconsultations for most of them), disruption in routines and lack of points of reference, adjustment in parenting and caring for children for the parents (with difficulties that could increase with prolonged duration of confinement), could have serious long-term effects, but also create opportunities.
So, the present study aim to document the experience of home confinement in children and adolescents with ASD and/or ADHD quarantined because of covid-19 outbreak in various socio-cultural contexts. The experiences reported by the children, their parents and their caregivers will help understand the psychological impact of quarantine.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interview by psychologists
Children and adolescent interview Parents interview Referring caregiver interview
Interview by psychologists
Interviews for children / teenagers and parents :
* The questions encourage a narrative
* Repeated interviews: during confinement, at the end of confinement, and 3 months after the end of confinement
* Interviews carried out by videoconference, by trained psychologists not involved in the care process
Interview for referring caregivers: a single interview of approximately 45 minutes, 3 months post-confinement
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interview by psychologists
Interviews for children / teenagers and parents :
* The questions encourage a narrative
* Repeated interviews: during confinement, at the end of confinement, and 3 months after the end of confinement
* Interviews carried out by videoconference, by trained psychologists not involved in the care process
Interview for referring caregivers: a single interview of approximately 45 minutes, 3 months post-confinement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* autism spectrum disorder (ASD) w/wo co-morbidities and/or attention-deficit - hyperactivity disorder (ADHD)
* aged 6 to 17 years (developmental age)
* cared by child psychiatry services involved in the study with continuing care (teleconsultations) during home confinement
* at least one parent consent to participate in the study
* child benefiting from a social security
Parents: one or both parents depending on availability and confinement configurations (childcare)
Referring caregivers: the referring caregiver will be identified at the time of the child's inclusion in the study
Exclusion Criteria
* Parents or children/adolescents who refuse to participate
* Parents unable to comply with the study requirements because of language or because of lack of access to visio or telephone conference facilities
6 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
University Hospital, Toulouse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Malika DELOBEL-AYOUB
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Toulouse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University hospital of Toulouse
Toulouse, Occitanie, France
Centre Hospitalier de Versailles
Le Chesnay, , France
Centre Hospitalier Esquirol
Limoges, , France
Hôpital Robert-Debré (AP-HP)
Paris, , France
Maison de Solenn (Hôpital Cochin AP-HP)
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC31/20/0151
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.